Screener
ADMA Biologics ADMA Share Buybacks
Share Buybacks at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Taxes paid on vested restricted stock units | (8,986) | (8,419) |
| Net proceeds from the exercise of stock options | 623 | 2,165 |
| Payment of end of term fee | - | (375) |
| Acquisition of treasury stock | (155,245) | - |
| Net cash used in financing activities | (39,546) | (7,079) |
| Net increase (decrease) in cash and cash equivalents | 48,390 | (12,862) |
| Cash and cash equivalents - beginning of period | 87,630 | 103,147 |
| Cash and cash equivalents - end of period | $$136,020 | 90,285 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's share buybacks?
- ADMA Biologics (ADMA) reported share buybacks of $25.05M in Q2 2026.
- What does share buybacks mean?
- Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.
Ask your AI about ADMA Biologics's share buybacks.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude